Korro Bio appoints Loic Vincent as Chief Scientific Officer
Korro Bio (KRRO) announced the appointment of Loic Vincent, Ph.D., as the Company’s Chief Scientific Officer. Prior to joining Korro, Dr.
Korro Bio: Promising Early Stage RNA Editing Company
Korro Bio's OPERA platform offers precise RNA editing for genetic diseases like Alpha-1 antitrypsin deficiency. Learn more on ...
Korro Appoints Biotech Industry Veteran, Loïc Vincent, Ph.D., as Chief Scientific Officer
Strengthens leadership team with additional key appointment of GaoZhong Zhu, Ph.D. as Senior Vice President of Chemistry, Manufacturing and Controls (CMC) & Technical Operations and promotion of ...
GlobalData on MSN10h
AIRNA secures $155m to bring RNA-candidate to clinic
The Series B funds will support the launch of a Phase I/II clinical trial for AIR-001 to advance its RNA editing pipeline.
Investing6d
Korro Bio reappoints CFO, names new principal accounting officer
Korro Bio, Inc. (NASDAQ:KRRO) announced today that Vineet Agarwal has resumed his role as Chief Financial Officer after returning from a medical leave that began on February 11, 2025. The company’s ...
Investing6d
Korro Bio reappoints CFO, names new principal accounting officer
Korro Bio, Inc. (NASDAQ:KRRO) announced today that Vineet Agarwal has resumed his role as Chief Financial Officer after returning from a medical leave that began on February 11, 2025. The company ...
BioPharma Dive1d
RNA editing biotech Airna adds $155M in funding
Airna will use the Series B round to launch a Phase 1/2 trial of its lead program for alpha-1 antitrypsin deficiency, a ...